Hydroxychloroquine for COVID-19: A Single Center, Retrospective Cohort Study
https://doi.org/10.47836/mjmhs.19.2.3
- Author:
Wen Chung Ho
1
;
Wei Xin Yong
2
,
3
;
Khai Shin Tan
4
;
Woh Yon Mak
5
;
Mandeep Kaur Gill
5
;
Agnes Hui Ching Lok
5
;
Shazwani Zulkifli
5
;
Salmah Idris
6
;
Khairil Erwan Khalid
4
;
Chee Loon Leong
4
;
Kang Nien How
2
,
3
Author Information
1. Department of Medicine, Hospital Serdang, Kajang, Selangor, Malaysia
2. Dermatology Unit, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia&
3. Dermatology Unit, Hospital Pengajar Putra Malaysia, University Putra Malaysia, Selangor, Malaysia
4. Infectious Disease Unit, Department of Medicine, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
5. Department of Pharmacy, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
6. Department of Pathology, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
- Publication Type:Journal Article
- Keywords:
Hydroxychloroquine, COVID-19, Coronavirus, Antiviral, Efficacy
- From:Malaysian Journal of Medicine and Health Sciences
2023;19(No.2):8-13
- CountryMalaysia
- Language:English
-
Abstract:
Introduction: The outbreak of coronavirus disease (COVID-19) in December 2019 called for a rapid solution, leading to repurposing of existing drugs. Due to its immunomodulatory effect and antiviral properties, hydroxychloroquine (HCQ) has been used in early 2020 for treatment of COVID-19 patients. This study was conducted to evaluate
the treatment outcome of HCQ monotherapy in Malaysia. Methods: A retrospective cohort study was conducted in
COVID-19 ward in Hospital Kuala Lumpur (HKL), from March to April 2020. A total of 446 COVID-19 patients were
recruited, only 325 patients were finally included for analysis. Statistical analysis was done using SPSS, with a significant value set at p<0.05. Results: The mean age of the patients were 38.5 ±15.5. They were majority male, (n=210,
64.6%) Malaysian (n=239, 73.5%) and Malay ethnicity (n=204, 62.8%). Ninety-one (28%) patients received HCQ
monotherapy. HCQ monotherapy was associated with worse outcome (OR: 10.29, 95% CI 1.17-90.80). There was a
significant difference in mean length of stay between those with and without HCQ treatment (t323=5.868, p<0.001,
95% CI, 2.56-5.31). The average length of stay for HCQ treated group was 3.84 days longer than those without
treatment. 6.6% of the patient receiving HCQ monotherapy encountered adverse drug effects. Conclusion: Similar
to study reported worldwide, our study demonstrated that HCQ did not improve length of stay and the outcome of
COVID-19 patients.
- Full text:11.2023my1453.pdf
